Medipost Co., Ltd

Won Il Oh

Yoon-Sun Yang

Hong Bae Jeon

Mi Yeon Lee

Sun Jae Kwon

Jong Wook Chang

Mee Hyun Jung

Sang Young Jeong

Ji Hyun Kim

Soon-Jae Kwon

Miyeon Kim

Hye Jin Jin

Dal Soo Kim

Dal-Soo Kim

Soon-jae Kwon

Yoon Sun Yang

Ju Yeon Kim

Disclosed is a method for culturing mesenchymal stem cells, comprising culturing mesenchymal stem cells in a medium containing calcium in a concentration of from 2.1 to 3.8 mM and magnesium in a concentration of from 1.0 to 3.0 mM under a hypoxic condition of 2 to 5% oxygen. The culturing method can increase the population of mesenchymal stem cells even with a small number of passages by improving mesenchymal stem cells in proliferative capacity and viability. In addition, the mesenchymal stem cells prepared by the culturing method are effectively used to treat or improve a pulmonary disease.

Method for culturing mesenchymal stem cells

Disclosed is a method for culturing mesenchymal stem cells, comprising culturing mesenchymal stem cells in a medium containing calcium in a concentration of from 2.1 to 3.8 mM and magnesium in a concentration of from 1.0 to 3.0 mM under a hypoxic condition of 2 to 5% oxygen. The culturing method can increase the population of mesenchymal stem cells even with a small number of passages by improving mesenchymal stem cells in proliferative capacity and viability. In addition, the mesenchymal stem cells prepared by the culturing method are effectively used not only as a safe cell therapeutic agent due to their lacking immunogenicity, but also as a cartilage regenerating medicine owing to their excellent secretion of cytokines.

A method for culturing mesenchymal stem cells. The method includes isolating mesenchymal stem cells having a size of 8 &#x3bc;m or less and culturing the mesenchymal stem cells in a medium containing calcium and magnesium and under a low oxygen condition. The method can significantly improve the proliferative capacity and differentiation potential of the mesenchymal stem cells.

Method for culturing mesenchymal stem cells according to cell size

Thrombospondin 1 (TSP-1), TSP-2, interleukin 17B receptor (IL-17BR) and heparin-binding epidermal growth factor-like growth factor (HB-EGF) associated with stem cell activity and use thereof.

Treating cartilage defect with UCB-MSC expressing TSP-2

Method of selecting stem cells having high chondrogenic differentiation capability

The present invention relates to a pharmaceutical composition for the prevention or treatment of neurological disorders, comprising an ICAM-1 (intercellular adhesion molecule-1) protein, or a fragment or a variant thereof as an active ingredient, which can increase the expression of neprilysin to remove amyloid-beta (A&#x3b2;), a cause of dementia, and is thus useful in preventing or treating a neurological disease including Alzheimer's disease.

Use of ICAM-1 for prevention or treatment of neurological diseases

Provided is a gene therapy composition for transferring one of a therapeutic gene, a maker gene, or a mixture thereof to a cell that expresses interleukin-8 (IL-8) or GRO-&#x3b1; and induces tropism of mesenchymal stem cells isolated from umbilical cord blood and/or the mesenchymal stem cells expanded from said mesenchymal stem cells (UCB-MSCs), wherein the cell-treating composition includes UCB-MSCs. Provided is a composition for treating disease related to a cell expressing IL-8 or GRO-&#x3b1;, that is, a brain tumor in gene therapy, by using UCB-MSCs. Provided is a composition or kit for diagnosing brain tumors, preventing brain tumors, treating brain tumors, or monitoring brain tumor treatment progression by using UCB-MSCs.

UCB-MSCs comprising a tumor suppressor gene reduce the size of an IL-8 or GRO-&#x3b1;expressing tumor

Growing community of inventors

Seoul, South Korea

Won Il Oh